I’ll take this opportunity to mention one of my favorite genetic stocks again. It’s Myriad Genetics (MYGN), and its business is developing and marketing tests that help assess the risk of disease based on a person’s genetic structure. Already, the firm has products that assess the risk of breast cancer, ovarian cancer, hereditary melanoma, adenomatous polyposis syndromes, hereditary colorectal cancer, and the risk of toxicity of 5-FU chemotherapy. Revenues have been growing strongly since 2004. The company turned profitable in fiscal 2008, which ended June 30. And it’s projected to grow earnings 44% in 2009 and 35% in 2010. ...
